Icagen halts trial enrollment on adverse event; GenVec gets milestone payment from Novartis;

@FierceBiotech: FDA takes second look at meta-analysis. Report | Follow @FierceBiotech

@JohnCFierce: Wrapping choices on this year's Fierce 15. Good group of companies. Rusty IPO window gives me plenty of companies to choose from | Follow @FierceBiotech

> Icagen has suspended further enrollment in the epilepsy study of ICA-105665 following the occurrence of a serious adverse event. The SAE occurred in the 600mg patient cohort following completion of the 500mg patient cohort. Icagen will be discussing the status of the study with its clinical advisors and with the FDA. Icagen release

> GenVec has achieved the first milestone in its collaboration with Novartis related to the development of treatments for hearing loss and balance disorders. The milestone was triggered by the successful completion of certain preclinical development activities. GenVec release

> Forest Laboratories has responded to the FDA's request for more information on COPD drug Daxas, which was rejected by an expert panel earlier this year. The agency didn't ask for any new trials of the drug. News

> A shareholder is suing Acura Pharmaceuticals following the FDA rejection of the company's painkiller Acurox. The shareholder claims CEO Andrew Reddick, among others, made misleading statements about the drug's clinical trial performance. Report

And Finally... Don't get enough sleep? A new study finds you could be at risk of dying prematurely. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.